Drug search by name

Sitagliptin and Metformin Extended-Release Tablets and Renal dysfunction

Result of checking the interaction of drug Sitagliptin and Metformin Extended-Release Tablets and disease Renal dysfunction for safety when used together.

Check result:

Sitagliptin and Metformin Extended-Release Tablets <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors. Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment. Linagliptin will not require a dose adjustment per manufacturer's information. Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses. However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.

Sitagliptin and Metformin Extended-Release Tablets

Generic Name: metformin / sitagliptin

Brand Name: Janumet, Janumet XR

Synonyms: Metformin and sitagliptin, Sitagliptin and Metformin

What is Sitagliptin and Metformin Extended-Release Tablets?